

Keyword Index for Volume 110

- ¹⁸F-FAMT 1985
¹⁸FLT-PET 875
25-hydroxyvitamin D 2772
3,5-diethyl-1,3,5-thiadiazine-2-thione (DETT) 63
3DPCR 2615
3-hydroxy-3-methylglutaryl coenzyme 802
4-hydroxy tamoxifen 1488
5-aza-2'-deoxycytidine 1923
5-fluorouracil 946
5hmC 668
8q24 164
- ABCB1* 1673
acceleration 2217
accreditation 850
actinic keratosis 520
active surveillance 2405
activin signalling 2604
acute myeloid leukaemia 783
ADAM9 2945
ADAMs 1535
adaptive design 1950
ADCC 1221
adenocarcinoma 1571, 2688
adherence 831
adhesion 146, 753
adjuvant chemotherapy 313
adjuvant therapy 1133, 1545
adolescent 1342
advanced adenoma 1228
advanced biliary tract cancer 2165
advanced neoplasia 1334
aerobic exercise 831
AFP 2090
AFP-L3 2090
age 1125
aggressiveness 1767
Akt 399, 935, 946, 1785, 1288, 2081
Akt signalling 899
albumin 2090, 2277
alcohol 242
aldehyde dehydrogenase 3A1 2593
ALDH1 430
ALDH1A1 protein 2935
aldo-keto reductase 1C3 1506
alkylating agents 2623
allergy 1825
alpha9 1269
alpha-fetoprotein 2277
amino-acid transporter 2030
amoeboid phenotype 2099
amphiregulin 648
amplification 2914
androgen receptor gene amplification 1655
aneuploidy 2159
angiogenesis 26, 107, 115, 469, 741, 946, 1027, 1034, 1179, 1269, 2700
angiogenic cytokines 441
animal welfare 928
anoikis 958
anti-angiogenesis 602, 882
anticipated delay 12
anti-inflammatory agents 1409
anti-oncomir 189
antitumour activity 1733
anti-tumour immunity 83
anxiety 868
APOBEC3 2615
- apoptosis 63, 164, 341, 421, 656, 753, 1645, 2144, 2224
apoptosis and cytotoxicity 146
appetite loss 1409
aromatase inhibitors 1133
ascites fluid 2269
ASCT2 2030, 2506
Asian 2187
aspirin 2378
atopy 1825
autoimmune disease 1825
autophagy 899, 2209
awareness 12
axitinib 875, 2821
- B7-H3 2072
BAP1 1058
Barrett's oesophagus 775, 2378
basal cell carcinoma 1855
BCAC 535
BCAS2 2144
 β -catenin 935, 2708
BCH 1985
Bcl-2 946, 1785
benchmarks 1917
benign behaviour 286
benign breast lesions 788
benzene 783
betaine 808
big five 1820
bilateral 1053
biliary cancer 882
bilirubin 2090
biliverdin 2116
biodistribution/toxicology 2441
biology 1985
biomarker strategy design 1950
biomarkers 26, 107, 123, 565, 648, 679, 928, 976, 1139, 1236, 2081, 2090, 2109, 2178, 2201, 2277, 2283, 2291, 2462, 2524, 2677, 2700, 2765, 2935
BIRC5 protein 2935
bladder cancer 679, 842, 1767, 1862, 1871, 2123, 2945
blue dye 2837
BMP-6 1634
BOADICEA 535
body mass index 1133
bone marrow cancer 2099
bone metastasis 1634
borderline behaviour 286
borderline/mildly dyskaryotic cytology 1579
bortezomib 656
bowel cancer 1705
bowel cancer screening 1705
BRAF 1045, 1359
BRAF mutation 1228
brain cancer 242, 1825
brain tumour 2354
BRCA1 530, 535, 1081
BRCA1/2 1074
BRCA2 530, 535, 1081
BRD4 1189
breast cancer 4, 146, 230, 535, 560, 565, 573, 715, 724, 831, 859, 916, 1081, 1088, 1133, 1288, 1367, 1378, 1420, 1681, 1688, 1744, 1898, 1908, 1958, 2072, 2144, 2195, 2209, 2327, 2412, 2524, 2623, 2765, 2772, 2847, 2855, 2905
breast cancer cells 1298, 2514
breast cancer incidence 224
breast cancer metastasis suppressor gene-1 2054
breast cancer risk 224, 2339
breast cancer stem cells 2063
breast conserving surgery 1420
breast density 1908
breast screening 556
breastfeeding 1074, 1367
BRMS1 2054
bromodomain 1189
bronchitis 2796
- CA-125 kinetics 1517
cachexia 1409
CAFs 724
calretinin 2040
cAMP 1278
cancer 479, 584, 1820, 1936, 2321
cancer epidemiology 7
cancer genomics 2615
cancer hallmarks 2935
cancer metabolism 330
cancer prevention 2361
cancer research 928
cancer risk 2361
cancer stem cell 430
cancer survival 1359
cancer survivors 868
cancer testes antigens 2450
cancer therapy 2496
cancer-associated fibroblast (CAF) 469
cancer-specific antigens 2450
cancer-stroma interaction (CSI) 469
capecitabine 1438
carbohydrate 1316
carbon ion radiotherapy 2389
carboplatin 256, 1923, 2975
carcinoma *in situ* 2604
carcinoma of unknown primary 208
cardiovascular 1338
carotene 792
case-control study 808, 1385, 2348
caspase 656
castration-resistant prostate cancer 2201, 2472
Caucasian 55
CCL7 (MCP-3) 686
CCNC 2246
CCR2 686
ccRCC 1778, 2261
CD105 1778
CD26 2232
CD43 146
CD44 916, 958, 1793
CD74 2040
CD8 2551
Cdc20 2905
CDH1 1053
CDK1 510
CDK19 2246
CDK8 2246
CDK8 submodule 2246
CDK9 1189
CDKN2A 2985
CEACAM1 1244
- cell cycle 656, 2434
cell cycle-specific transgene expression 94
cell growth 2583
cell migration 706, 2569
cell-free DNA (cfDNA) 363, 2054
CellSearch system 375
cellulitis 2796
central venous access catheters 1438
cervical cancer 34, 278, 1260, 1748
cervical cytology 1841
cervical intraepithelial neoplasia 1579
cetuximab 648
cetuximab resistance 2887
c-FOS 753
chemokine 741, 1179, 1992
chemokine receptor 1992
chemoprevention 2378
chemoresistance 1785, 1958, 2881
chemosensitivity 479
chemotherapeutic sensitivity 2269
chemotherapy 49, 271, 479, 908, 1488, 1759, 2165, 2462
chemotherapy resistance 2489
child 1342
childhood 1338
childhood leukaemia 1402
Chloroquine 899
cholangiocarcinoma 882
cholecystectomy 2348
choline 808
choline kinase-alpha 330
ChREBP 715
chronic lymphoid leukaemia 783
CIMBA 535
CIN 2159
circulating endothelial cells 1236
circulating microRNAs 2462
circulating tumour cells 375
CIS 668
cisplatin 341, 625, 1163, 1733, 1785
cisplatin resistance 123
CK19 2544
classification 1688
clear cell adenocarcinoma 2881
clear cell RCC 2537
clinical 1688
clinical features 2633
clinical outcome 459
clinical trials 551
cluster randomised controlled trial 2829
c-Met 1307
c-MYC copy number gain 2688
CNS tumour 286
coculture 1552
cohort 584, 2321
cohort study 214, 249, 1316, 2339, 2354
collagen I 409
colon 459
colon cancer 435, 459, 469, 817, 1211, 2081, 2310, 2544
colon neoplasms 2935
colorectal 648
colorectal adenoma 249
colorectal cancer 156, 164, 450, 530, 831, 875, 935, 946, 1001, 1008, 1014, 1221, 1316, 1359, 1595, 1606, 1614, 1847, 2159, 2178, 2300, 2551, 2716, 2728
colorectal cancer screening 1334, 1705
colorectal neoplasms 850

- communication 1101
 co-morbidity 573
 competing risk 1378
 computed tomography 2354
 concordance 1950
 conditionally replicating adenoviruses 2496
 consultation aid 1101
 contralateral prophylactic mastectomy 1081
 core biopsy 2195
 Coronin 1A 1622
 cost-effectiveness 1841, 2829
 covariates 304
 C-reactive protein 183
 cross-talk 1199
 CRPC 1634
 cutaneous squamous cell carcinoma 520
 CXCL12 1179
 CXCL16 1535
 CXCR4 686, 1179, 1288, 2261
 CXCR6 1535
 CXCR7 1179
 cyclic adenosine mono-phosphate 1278
 cyclooxygenase inhibitors 2378
 cyclophosphamide 1733
 cystectomy 1759
 cysteine 71
 cytidine deaminase 2615
 cytochrome P450 3A (CYP3A4) 2669
 cytokine receptor 133
 Cytokine-induced Killer (CIK) cell 1992
 cytokines 133, 733
 cytostatic drug 625
- DAP3 421
 database 584
 DCP 2090
 dedifferentiation 2923
 deep venous thrombosis 1118
 depression 868, 1409
 depressive symptoms 593
 derived neutrophil-lymphocyte ratio 2531
 dFdCTP 304
 diabetes 1825, 1847, 2361
 diagnosis 584, 1748
 diagnostic algorithm 1244
 diagnostic interval 584
 diagnostics 976
 diet 1392
 dietary intake 808
 dietary pattern 2785
 differentiation 199
 differentiation status 520
 diffusion-weighted imaging (DWI) 107
 diffusion-weighted MRI 616
 dihydropyrimidine dehydrogenase 2728
 discordance 2195
 discrete choice experiment 859
 disease control 1721
 disease progression 2537
 disease subtypes 1088
 distant metastasis 1378
 DJ-1 (PARK7) 1298
 DLBCL 369
 DNA damage response 1014
 DNA demethylation 668
 DNA methylation 775, 1923, 2054, 2123
 DNA repair gene mutations 1663
 DNMT3B 2131
 docetaxel 894, 2170, 2462, 2472, 2669
 Dock7 1307
 dose intensification 1413
 dosing schedules 1977
 double and triple mutations 2812
- drug resistance 1923, 2896
 drug sensitivity 330
 drug therapy 1943
 drug-drug interaction 888
 dual-imaging of virus and host cells 94
 DVT 1118
 dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) 107
- E2 1488
 early breast cancer 2187, 2450
 early diagnosis 584, 1001
 EBRT 2396
 E-cadherin 1053
 effectiveness 421, 551, 1841
 efficacy 551, 1977
 EGFR 648, 2116, 2688, 2716
 EGFR amplification mutation 1045
 EGFR and HER2 tyrosine kinase inhibitor 2647
 EGFR mutation 55
 EIF5A2 399, 1767
 elderly 313
 elective nodal irradiation 1420
 embryonic stem cells 2131
 Eμ-myc 928
 EMT 156, 695, 724, 1958, 2000
 EMT/MET 1497
 EMVI 19
 endometrial biopsy 609
 endometrial cancer 609, 2640, 2874
 endometrial cancer staging 609
 endometrial carcinoma 107
 endometrial carcinoma grading 609
 endometrial histology 609
 endometrial sampling 609
 endometriosis 1878
 endoplasmic reticulum stress 1488
 endothelial 1778
 endothelin B receptor 1027
 england 1322
 EPCAM 679
 EPCAM protein 2935
 epidemiology 242, 797, 1367, 1392, 1891
 epidermal growth factor receptor 882
 epigenetic silencing 636
 epigenetic-gene interaction 2123
 epigenetics 2874
 epiregulin 648, 2716
 epithelial ovarian cancer 42
 epithelial-mesenchymal transition (EMT) 958, 1298, 1767, 2514, 2569
 ERBB2 2985
 EREG 648
 eribulin mesilate 1497
 ERK1/2 1034, 1288
 ERRβ 2144
 ESMO 2640
 estimates of effect 1834
 ethnic 1322
 ethnicity 4, 224, 230, 1433
ex vivo model 2604
 expanded access 1721
 expression microarray profiling 520
 external quality assessment 850
 external validation 42
 Ezrin 695
- faecal immunochemical test 1334
 FAK 2747
 familial prostate cancer 1663
 family 1074
 family history of breast cancer 2339
 Fascin-1 2300
 fatigue 868, 1409
- FDG PET/CT 2209
 female breast cancer 1891
 FENSAM 2109
 fetal germ cells 668
 FGF receptors 1088
 FGFR amplification 967
 FGFR1 2914
 fibrinogen 984
 fibroblast growth factor receptor 320
 fibrosarcoma 1456
 FISH 1655
 FIT 1334
 flavopiridol 1189
 FLT-PET 2847
 fluid intake 797
 fluorescence *in situ* hybridisation 1571, 2688, 2914
 fluoropyrimidine 2728
 folate 1328, 2327
 FOLFIRI 875
 FOLFOX 875, 1438, 2662
 follow-up 19, 859, 2420
 food frequency questionnaire 797
 four-factor model 278
 FOXO1 1260
 FoxP3 1552, 2551
 Foxp3+ regulatory T cells 459
 free light chains 2277
 FSCN1 189
 FST 2144
 fucosyltransferase 156
- GA201 1221
 Gab1 1307
 galectin-1 1250
 galectins 741
 gallbladder cancer 882
 gallstones 2348
 gambogic acid 341
 gastric cancer 271, 421, 967, 1169, 1199, 1211, 1328, 1552, 1801, 2011, 2021, 2283, 2291, 2662, 2923
 gastro-oesophageal adenocarcinoma 1525
 GC 1244
 G-CSF 133, 1211
 G-CSFR 133, 1211
 gefitinib 55
 gemcitabine 83, 172, 304, 1481, 1943, 2472
 gender 1385
 gene expression 2662, 2728, 2738
 gene expression profile 1244
 gene expression profiling 1525
 gene function 1552
 genetic markers 2537
 genetic risk 2623
 genistein 1645
 germ cell tumour 2738
 germline mutation 1053
 GIST 1155
 glioblastoma 1179, 1307
 glioma 242, 1825, 2560
 global methylation level 2765
 Glut-1 715
 glyco-engineering 1221
 glycosylation 2021
 GNA11 1058
 Golgi phosphoprotein-3 (GOLPH3) 2250
 groin node 2837
 growth 2300
 growth factor receptors 1169
 guaiac faecal occult blood test (gFOBT) 1705
 guidelines 831
- haeme oxygenase-1 341
 haemolysis free 1001
 HAGE 2450
 haptokinesis 409
 haptotaxis 409
 HbA_{1c} 2361
 HBx 1066
 HCC 1811
 hCGβ 1759
 head and neck cancer 501, 593, 2677
 head and neck tumours 1587
 health status 573
 health-related quality of life 593, 2427
 help-seeking 12
 hepatectomy 1110
 hepatocellular carcinoma 733, 1066, 1110, 2090, 2277
 hepatocellular carcinoma subclasses 2708
 HER2 384, 625, 2209
 HER2 amplification 967
 HER2-positive 2756
 HER2-positive breast cancer 1139
 HER3 384
 HERBIS 1163
 herpes zoster 2796
 HGF 2716
 HIF-1α 115, 1250, 1066, 2209
 high risk 1074
 high-grade glioma 2655
 histological grade 2195
 histology 1385
 histomorphological marker 107
 histone deacetylase inhibitor 656, 1155
 histopathological regression 1712
 HLA Class I expression 459
 HLA-E 459
 HLA-G 459
 head and neck squamous cell carcinoma (HNSCC) 2116, 2887
 Hodgkin lymphoma 868
 hormonal therapy 1133
 hormone naïve 1655
 hospitalisation 1342
 HPV 1561, 1579, 1587, 1793
 HPV E7 1034
 HSF1 71
 Hsp 90 71
 human papillomavirus 489, 1587, 2369, 2804
 Human teratocarcinoma stem cells 2131
 humane end points 928
 hyperglycaemia 2361
 hypermethylation 2874
 hypermutation 2615
 hypertension 797
 hypofractionation 2217
 hypoxia 172, 715, 935, 1014, 2865
- ICAM-1 1801
 ID-1 1298
 ifosfamide 888
 IGF6P 2855
 IGF6P7 775
 IGFs 2865
 IL15 1673
 IL-6 2965
 IL-8 2965
 image cytometry 2159
 imaging 2420
 imatinib resistance 1155
 immune surveillance 459
 immunohistochemical subtypes 375

- immunohistochemistry 775, 1525, 1571
 immunosuppression 2965
 immunotherapy 1472
 immunotherapy vaccine 2450
 impact 2804
 improvement 1936
 incidence 4, 535, 797, 1322
 incidental breast cancer 788
 infection 2796
 infectious diseases epidemiology 7
 inflammation 208, 435, 1930, 2524
 inflammatory conditions 1825
 inflammatory parameter 369
 information exchange 1101
 infusion rate 304
 inguino-femoral lymphadenectomy 2837
 inhalation 1427
 inhibitors 1506
 Insulin-like growth factor 2855
 integrin 1269
 integrin $\alpha 5$ 764
 intensity-modulated radiotherapy (IMRT) 49, 297
 interaction 1359
 Interleukin-6 (IL-6) 469
 interleukin-2 1427
 interleukin-24 2496
 interleukin-8 2047
 intermediate-risk group 278
 international metastatic renal cell cancer database consortium 1917
 interphase-FISH 2537
 interval cancer 556, 560
 intervention 593
 intratumoural budding (ITB) 1008
 intratumoural subsites 2551
 invadopodia 189
 invasion 399, 1298, 1307, 2011, 2945
 invasive lobular breast cancer 1053
 ipilimumab 1721
 iRGD peptide 1481
 irinotecan 1148, 1733
 irradiation 1179
 JAK/STAT 133
 Japan 1316
 JMJ2B 1014
- KDR 2700
 Keap1 1785
 keratinocyte 199
 Ki-67 1561, 2847
 Ki67 promoter 2496
 kidney cancer 1622
 kinase and phosphatase inhibitors 2441
 KIT 1155
 KLF17 1298
 KLF4 450
 K-PD modelling 1517
 K-RAS 648, 1606, 2047 2874
 KRAS gene mutation 1148
- lactate dehydrogenase inhibitors 172
 laparoscopic radical cystectomy 842
 lapatinib 1139, 2647
 laryngitis 2796
 LASSO 2109
 LAT1 1985, 2506
 late complications 297
 late effects 1338
 late toxicity 49
 latent class modelling (LCM) 2756
 LBH589 1155
 LDH5 2217
 LDHA 2217
- leptin 1525, 1801
 leukaemia 1506, 2354
 Lgr5 2011
 ligands 2716
 likelihood functions 34
 LINE-1 repetitive sequences 2123
 liposarcoma 1456
 liquid chip technology 2812
 liquid chromatography tandem mass spectrometry 2489
 lobular carcinoma *in situ* 1053
 local 1456
 local recurrence 297
 localisation 1712
 locally advanced breast cancers 1413
 long noncoding RNA 164
 long-term survivors 2756
 long-term use 249
 low-dose radiation exposures 214
 LRIG1 1793
 lung 1936
 lung adenocarcinoma (AC) 991, 2047, 2583
 lung cancer 341, 764, 1385, 1834, 2427, 2688
 lung carcinoid 1244
 lung carcinoma 1545, 1571
 lung neoplasm 908
 LVS1 2640
 lymph node 2544
 lymph node and distant metastases 1008
 lymph node excision 34
 lymphatic metastasis 34
 lymphocyte subsets 2551
 lymphocytes 435
 lymphoid malignancies 2796
 lymphoma 928
 lysate microarray 2072
- magnetic field 1402
 magnetic resonance elastography 1727
 magnetic resonance imaging 1465
 magnetic resonance spectroscopy 625
 male 1744
 male breast cancer 1891
 malignant mesothelioma 510
 malignant pleural mesothelioma 984, 2040, 2232
 malignant progression 715
 mammary gland 2747
 mammary tumour 2747
 mammographic density 1898, 1908
 mammography 560, 2187, 2412
 mammospheres 2063
 MAPK pathway 520
 Markov model 2412
 mastectomy 2187
 mathematical model 7
 mathematical modelling 1517
 matrix metalloproteinase 916
 MDM2 656
 MDSCs 83
 MED13 2246
 Mediator 2246
 medulloblastoma 636
 melanoma 399, 802, 1427, 1721, 1855, 2489, 2496
 menarche 2339
 Merkel cell carcinoma 1446
 Merkel cell polyomavirus 1446
 mesenchymal stem cells 1199
 mesenchymal-epithelial transition 2514
 mesothelioma 2479
 meta-analysis 817, 1595, 1820, 1862, 1878, 2327, 2369, 2378, 2772, 2785
- metabolism 363
 metastases 441
 metastasis 256, 392, 450, 686, 695, 741, 753, 764, 916, 1288, 1497, 1748, 2000, 2011, 2072, 2099, 2144, 2300, 2310, 2537
 metastasised 2738
 metastatic 1125
 metastatic breast cancer 375, 384, 2756
 metastatic colorectal cancer 1148, 1438
 metastatic prostate cancer 2462
 metastatic renal cell carcinoma 1917
 methylation 808
 methylation-specific PCR 2054
 mGPS 1930
 MIB-1 2217, 2583
 mice 928
 microRNA 353, 991, 1199, 1614, 2072, 2945
 microRNA-133b 2310
 microsatellite instability 1228
 microvascular density 2700
 midline carcinoma 1189
 MIF 2040
 migration 146, 1801, 2865
 minimal residual disease 2544
 miR-126 2945
 miR-1260b 1645
 miR-145 2300
 miR-196a 1260
 miR-22 1250
 miR-29a 450
 miR-7 353
 miR-9 392
 MIRA 2224
 miRNA 764, 1260, 2291
 miRNA-9 636
 mismatch repair 2728
 MMP14 189
 MMPs 441
 MMSET 2662
 model 2640
 modelling 1834
 molecular 1688
 molecular subcategories 146
 molecular subgroups 2551
 monoclonal antibody 1221, 1472
 morbidity 2837, 2772
 mortality reduction 2412
 mouse model 894, 946
 MRI 625
 MSC 2955
 MSI 1359, 2159
 mTOR inhibitor 1917
 multi-arm trials 2178
 multi-colour FISH 2985
 multi-disciplinary 1936
 multimodality therapy 984
 multiphase contrast-enhanced MRI 616
 multiple myeloma 63
 multiplex testing 2812
 multivariate analysis 1712
 multivitamin 249
 mutant p53 2569
 mutation 1066
 MYC 2985
 myeloma 2224
- NADPH oxidase 2569
 Na⁺/H⁺ exchanger 1 916
 nasopharyngeal carcinoma 49, 297, 392 808, 2633
 nasopharyngeal neoplasms 1465
 NDC80 510
 neoadjuvant 430, 1139
 neoadjuvant chemoradiotherapy 19
 neoadjuvant chemotherapy 421, 1413, 1420, 2847
 neoadjuvant treated 1712
 neoplasms 1342
 neoplastic progression 2378
 network meta-analysis 2396
 neuroendocrine tumours 115
 neuropilin-1 1481
 neutropenia 271
 next-generation sequencing 1663, 2738
 NF- κ B 63, 341, 656, 695, 2965
 NICE guidelines 584
 nicotine 1785
 NLR 1930
 nomogram 34, 1110, 1943, 2261
 non-coding RNA 1614
 non-malignant 286
 non-melanoma 802
 non-small cell lung cancer (NSCLC) 55, 353, 363, 602, 991, 1236, 1930, 2030, 2054, 2812, 2914
 non-uptake 1705
 Notch1 2283
 NRF2 71
 NSC23925 2896
 nuclear 199
 nuclear workers 214
 nullipotent 2131
 Nur77 935
 nurse 593
 NUT 1189
- OATP1B 894
 observational research 551
 oesophageal adenocarcinoma 775, 2378, 2985
 oesophageal cancer 1027, 1328, 1985
 oesophageal squamous cell carcinoma 189, 2109, 2369, 2785
 oesophagogastric adenocarcinomas 1712
 oestradiol 1898
 oestrogen receptor 1488
 older 573
 ombrabulin 2170
 omega 6 1392, 2099
 omega-3 1392
 oncology 1101
 oncotherapy 83
 one-carbon metabolism 2123
 one-carbon metabolism pathway 1328
 open radical cystectomy 842
 oral administration 1269
 oral anticoagulant 1334
 oral bioavailability 2669
 oral contraceptives 1074, 1367
 organic food 2321
 oropharyngeal cancer 489
 oropharyngeal tumours 1587
 orthotopic ileal neobladder 842
 orthotopic mouse model 146, 2000
 OS 1811
 OSNA 2544
 osteopontin 1269
 osteosarcoma 2896
 outcomes 4, 551, 1456, 1688
 outcomes assessment 1917
 ovarian cancer 123, 133, 330, 625, 976, 1074, 1118, 1392, 1535, 1878, 1923, 2881, 2965, 2975
 ovarian cancer cells 753
 ovarian epithelial cancer 1517
 overall survival 42, 1433, 1917, 2021, 2261, 2283, 2700

- over-diagnosis 1841, 2412
 oxaliplatin 1733, 2472
- p16 1561, 1587, 1793
 p16ink4a 1587
 p16/Ki-67 dual-stained cytology 1579
 p185HER2-positive metastatic breast cancer patients 1968
 p27^{Kip1} 1260
 p53 656, 2224, 2747
 p95HER2 overexpression 1968
 PA28gamma 353
- paclitaxel 271, 1488, 1958, 2647, 2669, 2896, 2975
 paediatric ALL 1673
 paediatric cancer 636
 pain 1409
 pancreatic adenocarcinoma 1698
 pancreatic cancer 183, 313, 320, 1481, 2348
 pancreatic cancer cells 409
 pancreatic ductal adenocarcinoma 172, 2269
 pancreatic neoplasm 1943
 pancreatic stellate cells 409
 panobinostat 1155
 parity 1074
 PARP inhibitor 1977
 pathogenesis of testicular cancer 2604
 patient choice 573
 patient preferences 859
 patient survival 399
 patient-reported outcomes 2427
 patients' outcome 1968
 pazopanib 26, 888, 2647
 PC 1645
 PDE4D 1278
 PDE4D7 1278
 PE 1118
 peer 1936
 peer review 850
 pelvic lymph node 1748
 perineural invasion 1465
 peripheral blood leukocyte DNA 2765
 personalised medicine 1169, 1950, 2178, 2269, 2441
 personalised therapy 479
 personality 1820
 PET 1985
 PET-CT 363
 petroleum workers 783
 P-glycoprotein (P-gp/MDR1) 2669
 Pgp 2896
 pharmacodynamics 1977
 pharmacogenomics 304
 pharmacokinetic study 2655
 pharmacokinetics 888, 894, 1977, 2170
 pharmacokinetics and pharmacodynamics 2441
 pharyngitis 2796
 phase I 2434
 phase I/II clinical trial 2389
 phosphocholine 330, 625
 photodynamic therapy 1698
 physical activity 1862
 physical function 1409
 PI3K 1045, 2081
 PI3K expression 1968
 PI3K/mTOR inhibitors 2887
 PI3K/AKT/MDM2 2479
 PI3K/AKT/mTOR 2479
 piperlongumine 899
 plasma 392, 1001, 2291
 plasma miRNAs 976
- platelet-to-lymphocyte ratio 2524
 platinum 2881
 Plk inhibitor 2434
 PLK1 510
 PLR 1930
 pluripotent 2131
 polypeptide *N*-acetylgalactosaminyl transferase-5 (GalNAc-T5) 2021
 polyunsaturated fat 1392
 population based 868
 population pharmacokinetic model 304
 population-based cohort 797
 potassium intake 797
 powerline 1402
 PPP2CA 2000
 pre-diabetes 2361
 predictive 1606
 predictive biomarker 320, 984, 1525
 predictive factors 2195
 predictive markers 1169
 predictive testing 565
 premenopausal 1908
 preoperative AFU 1811
 preoperative biopsies 1008
 prevalence 2804
 prevention 1681
 primary care 584
 primary cell cultures 2269
 primary colorectal cancer 441
 prior therapy 2821
 progesterone receptor 565
 prognosis 115, 189, 208, 230, 363, 369, 489, 565, 679, 733, 775, 967, 984, 1110, 1228, 1236, 1465, 1535, 1545, 1552, 1561, 1595, 1614, 1673, 1744, 1759, 1778, 1847, 1878, 1943, 2011, 2040, 2081, 2090, 2159, 2250, 2283, 2524, 2531, 2551, 2560, 2583, 2905, 2914, 2923, 2975
 prognosis marker 1811
 prognostic 1606, 2021
 prognostic and predictive factor 2450
 prognostic biomarker 1525, 2054
 prognostic factors 183, 1465, 1712, 2030, 2165, 2427, 2506
 prognostic index 1688
 prognostic marker 399, 435, 991, 2047
 prognostic model 42, 2090, 2261
 prognostic significance 375
 prognostic value 501
 prognostics 976
 prognostic-score model 297
 progression-free survival 1433, 1917, 2700
 prokineticin 1446
 proliferation 1260, 1446, 2116, 2747, 2847
 prophylaxis 1427
 prospective cohort 797
 prospective cohort study 242
 prospective study 530, 792, 2772,
 prostate cancer 792, 831, 1278, 2000, 2099, 2217, 2389, 2396, 2405, 2593, 2829
 prostate cancer mortality 2829
 prostate cancer prognosis 1655
 prostate cancer stem cells 2593
 prostate-specific antigen 2829
 proteomic 2277
 proteomics 123, 1622, 1748, 2489
 PSA screening 2405
 psychosocial 593
 psychosomatic medicine 1820
 PTEN 384, 2874
- PTEN loss 1968
 pulmonary 1427
 pulmonary embolism 1118
 pulmonary metastasis 1110
 PVT-1 164
- qualitative 1681, 1705
 quality 1936
 quality improvement 850
 quality of care 551
 quality of life 868
 quantitative reverse transcription polymerase chain reaction (qRT-PCR) 991
- Rac1 706, 1307, 2677
 race 2796
 RAD21 1606
 radiation 214, 1472
 radiation therapy 2655
 radiation-induced cancer 2354
 radical resection 733
 radiological features 2633
 radiotherapy 256, 501, 908, 1420, 2217 2389, 2623, 2633
 randomised controlled study 842
 rapid genetic counselling and testing 1081
 Ras 1298
 reactive oxygen species (ROS) 2569
 rectal cancer 19, 430, 817
 recurrence 19, 1456, 2935
 reduction 928
 reduction mammoplasty 788
 refinement (3Rs) 928
 registHER 2756
 relapse 2420
 relative risk 1663
 relative survival 286
 renal cancer 616, 686
 renal cell cancer 797
 renal cell carcinoma 1125, 1250, 2250, 2700, 2821
 renal transplantation 1871
 reovirus 83
 replacement 928
 replication competent HSV-1 94
 residential distance at birth 1402
 residential history 1855
 resistance 479
 resistance exercise 831
 response biomarker 1727
RET gene rearrangement 1571
 retinoblastoma 2623
 retreatment 1721
 retrospective analysis 1125
 reverse-phase protein array 2081
 reversible posterior leukoencephalopathy syndrome 602
 RFS 1811
 RhoA 2310
 Rho/ROCK 1801
 rice 1316
 risk 1378, 1402, 1878
 risk assessment 214
 risk classification 2640
 risk factor 2738
 risk factors and sodium intake 797
 risk prediction 535
 risk stratification 2405
 RNAi 510
 ROS 899, 1034
 ROS generation 706
 ROS, reactive oxygen species 2116
 RRM2 1034
 RT-PCR 1488
- S-1 1163
 S100A13 2489
 safety 1721
 sarcoma 888, 1456
 sarcoma
 screening 1834, 2187, 2412, 2829
 second-line 2165
 second-line docetaxel 2662
 secretome 123
 securin 2905
 sedentary behaviour 817
 Se-methylselenocysteine 1733
 seminoma 256, 2604, 2738
 sentinel node 2837
 SERPINB3 2708
 serum 2277
 sex hormone-binding globulin 1898
 sFRP1 1645
 short-term survivors 2756
 SHP-2 2232
 sialoporphin 146
 side-population 2063
 signet ring cell cancer 1712
 single-nucleotide polymorphism 1673
 sirtuin inhibitor 656
 sisters 1074
 skin 199
 skin cancer 520, 802, 1855
 Skp2 1958
 slice cultures 479
 Smad4 946, 1645
 small cell 908
 small RNA 2738
 small-interfering RNA 2250
 smoking 242, 1359, 1385, 2339
 SNP 1088
 SNTA1 706
 socio-economic circumstances 1705
 soft tissue sarcoma 2420
 solid tumours 2434
 soluble CD146 1236
 somatic mutations 2812
 somatostatin 2232
 somatostatin receptor 2 115
 sorafenib 894, 1148, 1433, 2655, 2821
 squamous cell carcinoma 199, 1855, 2914
 squamous cell lung cancer (SCC) 991
 SSTR4 2232
 stage I 2187
 staging 2544
 standardised incidence ratio 788, 1871
 STAT3 133, 1014, 1767
 statin 802
 stem cells 1211
 stroma 441, 1744
 sunitinib 616, 1125, 1433, 2441, 2700
 sunlight 1058
 surgery 1712
 surveillance 1871
 survival 115, 208, 489, 556, 908, 1446, 1456, 1545, 1930, 2081, 2531, 2772
 survival analysis 1378, 2935
 survivin 199
 survivors 1338, 1342
 susceptibility 1088
 symptom recognition 12
 symptoms 584
 synchronous colorectal cancer 1228
 synovial sarcoma 1456
 systematic review 2785
 systemic inflammation 1409
- T lymphocytes 1595
 T regulatory cells 1595

- tamoxifen 1681, 2874
 TAp63 2310
 targeted therapies 1155, 1169, 2887
 targeted molecular therapy 1917
 technetium 2837
 teenage 1338
 temozolomide 2655
 temperature 928
 temporal lobe injury 49
 temporal lobe necrosis 2633
TERT 1058
 testis 2738
 testosterone 1898
 testosterone levels 2201
TGF- β 1, 1545, 1767
T_{H1} phenotype 2955
 therapeutic drug monitoring 2441
 therapeutic target 2677
 therapy 1189
 therapy resistance 2063
 thromboembolism 1118
 thymidylate synthase 2728
 thyroid 1322
 tissue culture 2604
 tissue microarray 946, 2040
TMPRSS4 764
TNF 1488
 TNM stage system 2109
 tongue cancer 2506
 tongue squamous cell carcinoma 695
 tonsillectomy 2348
 toxicity profile 1733
TP53 2874

TRAIL 656
 trans fat 1392
 transendothelial migration 2099
 transforming growth factor-beta
 (*TGF- β*) 156, 724, 946, 2569, 2708
 transitional cell carcinoma 26, 1759
 translation therapeutics 2450
 trastuzumab 1139, 1163, 1472, 2209
 trastuzumab-based therapies 1968
 treatment 1427
 treatment outcome 1721
 treatment resistance 2677
Treg 1552
 triple negative breast cancer 1045, 1413,
 1497, 2865
 tritium 214
 tropomyosin-related kinase B 2923
 tumour markers 1250
 tumoural 1778
 tumour 199, 535, 1269
 tumour burden 928
 tumour characteristics 1378
 tumour graft 1481
 tumour heterogeneity 2195
 tumour infiltrating leukocyte 1446
 tumour location 1595
 tumour microenvironment 1199, 2955
 tumour recurrence 1001, 2677, 2708
 tumour size prediction 1517
 tumour suppressor 353, 2144
 tumour viscoelasticity 1727
 tumour volume 363
 tumour-associated macrophages 686

 tumour-infiltrating inflammation 1595
 tumour-infiltrating lymphocytes 489,
 501, 2560
 tumour-initiating capacity 2514
 tumour-related circulating miRNA 1001
 tumour-stroma ratio 1744
Twist1 958
 two-stage design 1950
 tyrosine kinase inhibitor 320, 1148, 2655
 tyrosine kinases 2479

 ubiquitination 1785
UK 4
 ultrastaging 2837
 ultraviolet 1855
 update 535
 upper tract urothelial carcinoma 2531
 uptake 1681
 urgent referral 584
 urinary biomarkers 1622
 urine 679
 urothelial cancer 26
 urothelial carcinoma 1759
 user interface 535
 uterine leiomyoma 2246
 UV exposure 1058

 vaccine 2804
 vaginal cancer 1561
 validation study 2531
 vascular disrupting agent 2170
 vascular endothelial growth factor recep-
 tor tyrosine kinase inhibitor 2647

 vascular targeting agents 1727
 vascularisation 2855
 vasculogenesis 1179
 vegetable 792
VEGF 469, 1433
VEGF inhibitor 1917
VEGF receptor inhibitor 2821
VEGF-A 2700
 venous invasion 19
 verteporfin 1698
 vincristine 1189
visitatie 850
 vitamin D 2772
 volasertib 2434
 vulval cancer 2837

 warning signs 12
WNT5A 1634
 women 2321

 X-chromosome-linked inhibitor of
 apoptosis (*XIAP*) 2881
xCT 2506
XELOX 1438
 xenograft 1977, 2855, 2975

 young adult 1342
 young women 1841

 ziv-aflibercept 602
ZNF143 2583
ZNF217 2985